

### **DSCR8 Antibody (N-term) Blocking Peptide**

Synthetic peptide Catalog # BP6322f

### **Specification**

### DSCR8 Antibody (N-term) Blocking Peptide - Product Information

**Primary Accession** 

**Q96T75** 

# DSCR8 Antibody (N-term) Blocking Peptide - Additional Information

#### **Other Names**

Down syndrome critical region protein 8, Cancer/testis antigen 25, CT25, Malignant melanoma-associated protein 1, MMA-1, Protein MTAG2, DSCR8, C21orf65, MTAG2

### Target/Specificity

The synthetic peptide sequence used to generate the antibody <a href=/product/products/AP6322f>AP6322f</a> was selected from the N-term region of human DSCR8. A 10 to 100 fold molar excess to antibody is recommended. Precise conditions should be optimized for a particular assay.

#### **Format**

Peptides are lyophilized in a solid powder format. Peptides can be reconstituted in solution using the appropriate buffer as needed.

### **Storage**

Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C.

#### **Precautions**

This product is for research use only. Not for use in diagnostic or therapeutic procedures.

## DSCR8 Antibody (N-term) Blocking Peptide - Protein Information

### Name DSCR8 (HGNC:16707)

### **Tissue Location**

Expressed in numerous tissues; not found in breast, heart, small intestine and liver (PubMed:12036297). Isoform 1: Predominantly expressed in the testis (PubMed:11920614, PubMed:15472897). Isoform 3: Predominantly expressed in the testis, at lower level in the placenta, during malignant progression of melanocytic tumors and in several tumors of varying origins (PubMed:11920614, PubMed:15472897). Isoform 4: Predominantly expressed in the testis, at lower level in the placenta, during malignant progression of melanocytic tumors and in several tumors of varying origins (PubMed:11920614, PubMed:15472897). Isoform 5: Predominantly expressed in the testis (PubMed:11920614, PubMed:15472897).

# **DSCR8 Antibody (N-term) Blocking Peptide - Protocols**



Provided below are standard protocols that you may find useful for product applications.

# • Blocking Peptides

# **DSCR8 Antibody (N-term) Blocking Peptide - Images**

# DSCR8 Antibody (N-term) Blocking Peptide - Background

Down syndrome, which is the most common birth defect, is caused by trisomy 21. Studies of patients with partial trisomy 21 have defined a 1.6-Mb region between the DNA marker LA68 and ERG in 21q22.2 as the Down syndrome critical region (DSCR). DSCR8 is expressed in numerous tissues, but is not found in breast, heart, small intestine and liver.

### DSCR8 Antibody (N-term) Blocking Peptide - References

Toyoda, A., et al., Genome Res. 12(9):1323-1332 (2002). Reymond, A., et al., Genomics 79(6):824-832 (2002). de Wit, N.J., et al., Int. J. Cancer 98(4):547-553 (2002). Dahmane, N., et al., Genomics 48(1):12-23 (1998).